Patents Examined by Christina Bradley
  • Patent number: 11357863
    Abstract: The present invention provides peptide conjugates capable of translocating across the cytoplasmic membrane of a mammalian cell and inhibiting the Notch signalling pathway. Peptide conjugates, compositions and methods of the invention are useful for targeting chemo-resistant cancer stem cells.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 14, 2022
    Assignee: Anastasis Biotec Limited
    Inventor: Agamemnon Epenetos
  • Patent number: 11357862
    Abstract: An isolated or a synthetic targeting peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 8 is disclosed. The targeting peptide may be conjugated to a component selected from the group consisting of polymeric micelles, lipoprotein-based drug carriers, nanoparticle drug carriers, a chemotherapeutic agent, a micelle, a liposome, dendrimers, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a prostate cancer cell, a stem cell, and an imaging agent. Also disclosed are a kit for imaging and detecting the presence of prostate cancer cells in vivo or in vitro, and a composition for treating prostate cancer, inhibiting prostate cancer cell growth, inducing prostate cancer cell cytotoxicity, and/or increasing the survival rate in a prostate cancer patient.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: June 14, 2022
    Assignee: Academia Sinica
    Inventors: Han-Chung Wu, Chen-Yun Yeh
  • Patent number: 11357819
    Abstract: The present invention is a cytocidal agent including a peptide consisting of an amino acid sequence represented by SEQ ID NO: 1 and a site selectively binding to a target molecule, in which the peptide consisting of an amino acid sequence represented by SEQ ID NO: 1 is a peptide exclusively consisting of L-amino acids, a peptide in which, in amino acid sequences represented by SEQ ID NO: 1, the first to the 14th amino acids are D-amino acids, and the 15th to 19th amino acids are L-amino acids, a peptide in which, in amino acid sequences represented by SEQ ID NO: 1, the first to 14th amino acids are L-amino acids, and the 15th to the 19th amino acids are D-amino acids, or a peptide exclusively consisting of D-amino acids.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: June 14, 2022
    Assignee: FUJITA ACADEMY
    Inventors: Kazuhiro Sugihara, Naohiro Kanayama, Yuichiro Onodera, Toshiaki Shibata, Michiko Fukuda, Motohiro Nonaka
  • Patent number: 11358988
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: June 14, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • Patent number: 11331370
    Abstract: Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified lectins. Also disclosed are methods for making and using the compositions.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: May 17, 2022
    Assignees: The Population Council, Inc., The United States of America
    Inventors: Barry R. O'Keefe, Melissa Robbiani, José A. Fernández Romero
  • Patent number: 11319347
    Abstract: An object of the present invention is to provide a novel cyclic peptide compound excellent in cell membrane permeability, a method for producing the same, a composition for screening use, and a method for selecting a cyclic peptide compound that binds to a target substance. According to the present invention, a peptide compound represented by Formula (1) or a salt thereof is provided. In the formula, the symbols have the meanings as defined in the specification of the present application.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: May 3, 2022
    Assignee: FUJIFILM Corporation
    Inventors: Masaaki Inoue, Takashi Tamura, Yuji Yoshimitsu, Takahiro Hohsaka, Takayoshi Watanabe
  • Patent number: 11299516
    Abstract: The present invention describes a unique method of treating cancer with the administration of an improved DAGRS™ construct which functions as a humanized agent specifically targeting cancer cells in vivo. A specific DAGRS™ is described constructed of a humanized drug delivery biologic, carboxyl to an Apoptin fragment consisting of Apoptin's proline-rich SH3-binding fragment, a spacer, and a MAP kinase (MAPK) phosphorylation site, in replacement of the SH3-binding domain at HIV-1 TAT's amino terminus. Apoptin is a viral protein with incumbent immunogenicity and toxicity in humans. Improved DAGRS™ constructs are described that replace the viral VP3 peptide with human AKT peptide or derivative, all equivalently spaced 11 amino acids from the initial proline to the beginning of the MAPK phosphorylation site, through which technology the DAGRS™ is fully humanized. DAGRS™ provide for improved bioavailability, enhanced specific activity, and low toxicity for in vivo treatment of cancer.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: April 12, 2022
    Inventor: David I. Cohen
  • Patent number: 11298401
    Abstract: Compositions comprising a mixture of an antimicrobial cationic polypeptide and a second pharmaceutically-acceptable polymer are disclosed, as well as methods and uses thereof for the treatment and prevention of infections that occur when our natural barriers of defense are broken.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: April 12, 2022
    Assignee: Amicrobe, Inc.
    Inventors: Michael P. Bevilacqua, Diego Benitez, Jarrod A. Hanson
  • Patent number: 11285219
    Abstract: The present description relates to peptidomimetic foldamers, and their synthesis. In particular, the description provides peptide-amino urea hybrid peptidomimetic foldamers comprising an alpha amino acid peptide portion and an oligourea portion.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: March 29, 2022
    Assignees: UREKA SARL, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Robert H. Zimmer, Gilles Guichard, Juliette Fremaux, Sebastien Goudreau, Claire Venin, Laura Mauran
  • Patent number: 11266609
    Abstract: The present invention relates to compositions comprising Cannabidiol (CBD) or pharmaceutically acceptable salts thereof, and bacitracin or pharmaceutically acceptable salts thereof and/or daptomycin or pharmaceutically acceptable salts thereof. The compositions show a synergistic effect in the inhibition of growth of Gram-positive bacteria. Thus, the compositions according to the invention may e.g. find use as medicaments in the treatment of Gram-positive bacterial infections.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: March 8, 2022
    Assignee: Syddansk Universitet
    Inventors: Janne Kudsk Klitgaard, Claes Søndergaard Wassmann
  • Patent number: 11260101
    Abstract: Provided are a repair peptide for use in promoting post-traumatic tissue repair and regeneration, and an application thereof. The repair peptide is a linear or cyclic peptide which is 4-15 amino acids in length and which contains four or more consecutive GPANVET core sequences.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: March 1, 2022
    Assignee: Jinan University
    Inventors: Xiaojia Chen, An Hong
  • Patent number: 11260108
    Abstract: The invention relates to MIC-1 compounds for use in the prevention and/or treatment of obesity, wherein the MIC-1 compounds is administered simultaneously, separately or sequentially with a GLP-1 compound.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: March 1, 2022
    Assignee: Novo Nordisk A/S
    Inventor: Sebastian Beck Joergensen
  • Patent number: 11261236
    Abstract: The present invention relates to: a fusion peptide comprising a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide; and a use thereof and, more specifically, to: a fusion peptide in which a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide are sequentially linked; a composition for preventing or treating thrombotic disorders, containing the same as an active ingredient; a method for treating thrombotic disorders; and a therapeutic use. According to the present invention, CLT-sFt-?Pn DCNC as a novel plasmin-based thrombolytic nanocage has: an effect of targeting a site at which thrombus is present; a low sensitivity to inhibitors present in the circulatory system; pharmacological activity strongly destroying both arterial and venous thrombi; and no side effects of bleeding, and thus can be very useful in developing an agent for preventing or treating thrombotic disorders.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: March 1, 2022
    Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Soyoun Kim, Jun Young Seo, In San Kim
  • Patent number: 11260111
    Abstract: Disclosed are applications of a mussel adhesive protein or preparations thereof in suppression of skin inflammations. Specifically disclosed are applications of a mussel adhesive protein, preparations thereof and applications thereof in dermatitis, eczema, skin ulcer, technologies related to burns (comprising skin grafting), perniones, surgical incisions, herpes, abrasions, scars, psoriasis, erythema multiforme, skin damage after radiotherapy, skin cancers, folliculitis, urticaria and drug eruption, and applications in sunburn, polymorphous light eruption, pathological alopecia (comprising hair transplant), acne vulgaris, rosacea (that is, acne rosacea), and the like, and applications in the treatment of otitis externa.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: March 1, 2022
    Assignee: Jiangyin Bengt I. Samuelsson Institute of Life Science Co., Ltd.
    Inventors: Bengt Ingemar Samuelsson, Min Gao
  • Patent number: 11241502
    Abstract: The present invention provides stable pharmaceutical compositions of pegylated carfilzomib compounds, methods for preparing the compositions, and uses of the compositions for treating cancer, including hematologic malignancies such as multiple myeloma. The compositions can be stored in frozen form or lyophilized to dry solid form.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: February 8, 2022
    Assignee: AMGEN INC.
    Inventors: Alona Teran, William Callahan, Qahera Munaim, Rahul Kaushik
  • Patent number: 11224565
    Abstract: Methods of treating aging related skin changes and of increasing skin thickness with topical administration of N-acyldipeptide derivatives are described. Compositions comprising N-acyldipeptide derivatives, are therapeutically effective for increasing skin thickness, and for treating extrinsic and intrinsic aging and aging related skin changes, such as fine lines, wrinkles, photoaging, hyperpigmentation, laxity, age spots, lentigines, mottled skin, and cellulite.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: January 18, 2022
    Assignee: Neostrata Company, Inc.
    Inventors: Ruey J. Yu, Eugene J. Van Scott
  • Patent number: 11225510
    Abstract: The subject invention pertains to a modified lantibiotic containing an intact cysteine at the C-terminus, particularly, a cysteine that is not decarboxylated and that contains a free carboxyl group. Derivatives of the modified lantibiotic comprising a moiety conjugated to the carboxyl group of the terminal cysteine are also provided. A bacterium that produces a modified lantibiotic having an intact cysteine at the C-terminus are also provided, wherein the bacterium is genetically modified to inactivate a gene that encodes a decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic. Methods of producing a modified lantibiotic having an intact cysteine at the C-terminus by culturing a bacterium that synthesizes the modified lantibiotic and purifying the lantibiotic are also provided. Mutants of lantibiotics, particularly, mutacin 1140 having higher anti-bacterial activity or higher bacterial expression compared to mutacin 1140 are also provided.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: January 18, 2022
    Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: James L. Smith, Jerome Escano
  • Patent number: 11219663
    Abstract: Provided a composition excellent in biological safety and capable of enhancing GLP-1 secretion-accelerating effect due to a sweetening agent. The content ratio of the cyclic dipeptide or a salt thereof and a sweetening agent in a composition is controlled to fall within a specified range. Owing to this, GLP-1 secretion-accelerating effect due to the sweetening agent is enhanced.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: January 11, 2022
    Assignee: SUNTORY HOLDINGS LIMITED
    Inventors: Toshihide Suzuki, Natsumi Hiraki
  • Patent number: 11207372
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: December 28, 2021
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Patent number: 11208433
    Abstract: The present invention relates to a peptide for inhibiting skin inflammation and a pharmaceutical composition and a cosmetic composition for preventing or treating skin inflammation including the same. Since the peptide, pharmaceutical composition and cosmetic composition are effective for improving symptoms of skin inflammation caused by atopic dermatitis and the like, they are useful for preventing, improving or treating skin inflammation.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: December 28, 2021
    Assignee: AVIXGEN Inc.
    Inventors: Yi Yong Baek, Jun Sub Choi, Hye Cheong Koo